Holen Sie sich die Stockscreener-App
8.31
0.60%
-0.05
Handel nachbörslich:
8.31
Corbus Pharmaceuticals Holdings Inc Aktie (CRBP) Neueste Nachrichten
Why Corbus Pharmaceuticals Holdings Inc. stock could outperform in 2025Gap Up & Weekly Top Performers Watchlists - ulpravda.ru
Will Corbus Pharmaceuticals Holdings Inc. stock continue upward momentumMarket Trend Review & Weekly Top Gainers Trade List - ulpravda.ru
Will Corbus Pharmaceuticals Holdings Inc. (3371) stock sustain dividend payoutsJuly 2025 Retail & Free Verified High Yield Trade Plans - ulpravda.ru
Aug Outlook: Will Corbus Pharmaceuticals Holdings Inc. stock continue upward momentum - ulpravda.ru
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
News | postregister.comCorbus Pharmaceuticals Holdings, Inc.Common Stock (Nasdaq:CRBP) Detailed Stock Data - FinancialContent
Revenue per share of Corbus Pharmaceuticals Holdings Inc – LSE:0SZI - TradingView — Track All Markets
J.P. Morgan Healthcare Conference - MarketScreener
Corbus Pharmaceuticals to Present Corporate Overview at the 2026 Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
Corbus Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Corbus Pharmaceuticals shares rise on encouraging safety results for experimental obesity drug - MSN
While hedge funds own 24% of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), retail investors are its largest shareholders with 46% ownership - Yahoo Finance
Corbus Pharmaceuticals Holdings Inc. stock underperforms Friday when compared to competitors - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
How Corbus Pharmaceuticals Holdings Inc. (CRBP) Affects Rotational Strategy Timing - Stock Traders Daily
Downgrade Watch: Will Corbus Pharmaceuticals Holdings Inc 3371 stock top growth indexesMarket Growth Summary & Daily Volume Surge Trade Alerts - moha.gov.vn
Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Below Fifty Day Moving AverageShould You Sell? - MarketBeat
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Corbus Pharmaceuticals announces retirement of board member Holmer - MSN
Can Corbus Pharmaceuticals Holdings Inc. stock sustain institutional interest2025 EndofYear Setup & Fast Exit and Entry Trade Guides - DonanımHaber
Will Corbus Pharmaceuticals Holdings Inc. stock outperform growth indexesQuarterly Trade Review & Growth-Oriented Investment Plans - DonanımHaber
Will Corbus Pharmaceuticals Holdings Inc. stock outperform value stocksJuly 2025 Drop Watch & Consistent Return Strategy Ideas - DonanımHaber
Can Corbus Pharmaceuticals Holdings Inc. stock continue upward trendJuly 2025 PreEarnings & Free Reliable Trade Execution Plans - DonanımHaber
Corbus Pharmaceuticals Announces Retirement of Board Member Holmer - The Globe and Mail
How resilient is Corbus Pharmaceuticals Holdings Inc. stock in market downturnsJuly 2025 Sector Moves & AI Based Trade Execution Alerts - Улправда
Will Corbus Pharmaceuticals Holdings Inc. stock return to pre crisis levelsJuly 2025 Update & Entry and Exit Point Strategies - Улправда
Volume Report: How resilient is Corbus Pharmaceuticals Holdings Inc. stock in market downturnsPortfolio Gains Report & Growth Oriented Trade Recommendations - ulpravda.ru
Cormorant Asset Management, LP Reduces Stake in Corbus Pharmaceu - GuruFocus
Corbus Pharmaceuticals (CRBP) director Alan Holmer resigns from board to retire - Stock Titan
Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Alan Holmer from its Board of Directors, Effective December 31, 2025 - marketscreener.com
Rally Mode: How resilient is Corbus Pharmaceuticals Holdings Inc. stock in market downturnsJuly 2025 EndofMonth & Free Expert Verified Stock Movement Alerts - Улправда
Corbus Pharmaceuticals Holdings Inc. Stock Slides 8.6%, Underperforms Peers - 富途牛牛
Corbus Pharmaceuticals Holdings Inc. Stock Underperforms Wednesday When Compared To Competitors - 富途牛牛
Cormorant Asset Management, Lp Sells 30,029 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat
Corbus Pharmaceuticals (CRBP) insider reports 30,029-share stock sale - Stock Titan
Discipline and Rules-Based Execution in CRBP Response - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. (CRBP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
CRBP stock surged 36% pre-market – what did its obesity treatment drug study reveal? - MSN
Corbus Pharmaceuticals (CRBP) Reports Phase 1 Study Results for Obesity Drug - GuruFocus
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Corbus declines following early-stage results on oral obesity asset CRB-913 (CRBP:NASDAQ) - Seeking Alpha
CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal? - Stocktwits
CRBP: Corbus Pharmaceuticals' Promising Phase I Study Sparks Int - GuruFocus
CRBP: CRB-913 induced rapid, significant weight loss with minimal side effects in early obesity trials - TradingView — Track All Markets
Corbus Pharmaceuticals Reports Phase 1a Obesity Drug Data Showing Weight Loss - marketscreener.com
Corbus reports positive phase 1 results for obesity drug CRB-913 - Investing.com
Corbus Pharmaceuticals Advances Obesity Treatment with CRB-913 - TipRanks
Corbus Pharmaceuticals Reports Results From Phase 1A Study Of Oral CB1 Inverse Agonist CRB-913 For The Treatment For Obesity Demonstrating Favorable Safety Profile And Emerging Evidence Of Weight Loss - TradingView — Track All Markets
Corbus Pharmaceuticals (CRBP) Advances Obesity Treatment with CR - GuruFocus
Corbus Pharmaceuticals Announces Phase 1a Study Results of CRB-913 - TradingView — Track All Markets
Corbus Pharmaceuticals stock rises after promising obesity drug safety data By Investing.com - Investing.com UK
Corbus reports positive phase 1 results for obesity drug CRB-913 By Investing.com - Investing.com South Africa
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):